Subject Expert Committee ( SEC) has recommended granting an emergency use authorisation to Bharat Biotech's #Covaxin for children aged between 2-18.
The SEC has submitted its recommendation to the Drugs Controller General of India (DCGI) for final approval.
Bharat Biotech had last week submitted Phase 2/3 clinical trials data of children's trials to the DCGI. #CovidVaccine #VaccineForKids
Also Read-[ Ссылка ]
----------------------------------------------------------------------------------------------------------
We are active on social media! Follow us:
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
Stay updated with our Apps:
For Android users: [ Ссылка ]
iOS users: [ Ссылка ]
For more videos: [ Ссылка ]
For all the important news: [ Ссылка ]
